Theravance Biopharma (TBPH) Return on Sales [ROS] (2013 - 2026)
Theravance Biopharma's Return on Sales [ROS] was -39.93% in Q2 2026, down 29.52 percentage points from -10.40% a year earlier but up 13.65 percentage points from the prior quarter.
Powered by 
Analysis
Theravance Biopharma (TBPH) Return on Sales [ROS] (2013 - 2026) Analysis & Trends
On a trailing twelve-month basis, Theravance Biopharma's Return on Sales [ROS] was -4.03% through Jun 30, 2026, up 44.15 percentage points year-over-year; for FY2025, it was -3.35%, up 69.57 percentage points from FY2024.
- Return on Sales [ROS] has now increased for four consecutive years, with a five-year change of +410.84 percentage points (FY2020 to FY2025).
- In earlier years, Return on Sales [ROS] was -72.92% in FY2024 (+24.66 pp), -97.58% in FY2023 (+81.51 pp), -179.09% in FY2022 (+286.97 pp) and -466.06% in FY2021 (-51.87 pp).
- Quarterly Return on Sales [ROS] has moved between -406.36% (Q3 2021) and 43.61% (Q4 2025) over five years.
- Compared with a year earlier, Return on Sales [ROS] was higher in four of the last eight quarters, with an average year-over-year change of +24.57 percentage points.
- The best year-over-year quarter for Return on Sales [ROS] over five years was Q3 2022 (a gain of 332.92 percentage points); the worst was Q2 2026 (a drop of 29.52 percentage points).
- Per Business Quant data, TBPH's Return on Sales [ROS] in the three quarters before Q2 2026 was -53.58% (Q1 2026), 43.61% (Q4 2025) and -32.29% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Theravance Biopharma | 883.70 Mn | -543.66 Mn | - | -39.93% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.93% |
| Mar 31, 2026 | -53.58% |
| Dec 31, 2025 | 43.61% |
| Sep 30, 2025 | -32.29% |
| Jun 30, 2025 | -10.40% |
| Mar 31, 2025 | -93.80% |
| Dec 31, 2024 | -49.06% |
| Sep 30, 2024 | -64.25% |
| Jun 30, 2024 | -110.16% |
| Mar 31, 2024 | -77.27% |
| Dec 31, 2023 | -35.53% |
| Sep 30, 2023 | -55.82% |
| Jun 30, 2023 | -117.27% |
| Mar 31, 2023 | -239.15% |
| Dec 31, 2022 | -119.00% |
| Sep 30, 2022 | -73.44% |
| Jun 30, 2022 | -243.25% |
| Mar 31, 2022 | -291.77% |
| Dec 31, 2021 | -375.80% |
| Sep 30, 2021 | -406.36% |
API Access
Theravance Biopharma Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=TBPH&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "TBPH", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=TBPH&period=max&api_key=YOUR_API_KEY");
const data = await res.json();